Analytics group Phesi partnered with Accenture to release the first of several reports on the use of RWD (real world data) and RWE (real world evidence) in the drug development pipeline. One of the key benefits discussed in the report is reduced costs. Oncology trials are especially expensive, with research and development costs reported at $2.77 billion. Gen Li, President and CEO of Phesi, sees RWD and RWE (real world evidence) as important components of clinical development.
Gen Li notes, “The key takeaway from this report is to help demonstrate the “art of the possible” in clinical development, brought to us by available patient data, and the enhanced ability to gain and utilize patient data without subjecting actual patients to the comparator arm part of the clinical trial process, as well as reducing costs and accelerating the delivery of innovative new drugs to patients.” Read more here.
(Source: Jenni Spinner, Outsourcing-Pharma, 3/29/21)